{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:55:56Z","timestamp":1789433756543,"version":"build-2803163510"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100024679","name":"Advanz Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024679","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Cefepime\/enmetazobactam is a new \u03b2-lactam\/\u03b2-lactamase inhibitor combination with broad-spectrum activity against multidrug-resistant Enterobacterales, including OXA-48-producing isolates. Furthermore, cefepime and enmetazobactam have demonstrated similar and excellent intrapulmonary penetration, supporting the use of this new antibiotic combination in the treatment of hospital-acquired pneumonia. This study evaluated the\n              <jats:italic>in vivo<\/jats:italic>\n              efficacy of cefepime\/enmetazobactam in a murine neutropenic pneumonia model infected with various OXA-48-producing\n              <jats:italic>K. pneumoniae<\/jats:italic>\n              strains. Mice were subcutaneously administered with cefepime (100 mg\/kg\/q2h), alone or combined with enmetazobactam (30 mg\/kg\/q2h), or intraperitoneally with meropenem (100 mg\/kg\/q2h) at 2 h post-infection. Mice were euthanized at 26 h post-infection for bacterial enumeration in lungs and spleen. A robust growth was achieved in untreated control mice. Cefepime alone or meropenem had no effect on reducing the bacterial burden in lungs after a 24-h period of treatment. The addition of enmetazobactam to cefepime resulted in a 2-log\n              <jats:sub>10<\/jats:sub>\n              CFU\/g bioburden reduction in lungs compared to 26-h controls for all strains, including the strain harboring the highest MIC (= 8 \u00b5g\/mL) to cefepime\/enmetazobactam. When changes of bacterial burden were assessed relative to 2-h controls, bacterial stasis was observed. These data highlight the limited\n              <jats:italic>in vivo<\/jats:italic>\n              activity of meropenem against OXA-48-producing Enterobacterales despite\n              <jats:italic>in vitro<\/jats:italic>\n              susceptibility. Conversely, cefepime\/enmetazobactam with a human-mimicking regimen demonstrated a significant antibacterial effect in the pneumonia model induced by three OXA-48-producing\n              <jats:italic>K. pneumoniae<\/jats:italic>\n              strains, compared with cefepime or meropenem at 24 h post-infection. Therefore, cefepime\/enmetazobactam may be a new alternative for lung infections due to Enterobacterales producing OXA-48.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>IMPORTANCE<\/jats:title>\n            <jats:p>\n              Third-generation cephalosporin-resistant\n              <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n              with extended-spectrum \u03b2-lactamases as principal resistance determinants are classified as critical priority pathogens. Their increasing occurrence has led clinicians to widely use carbapenems. Accordingly, carbapenem resistance in\n              <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n              has spread in recent decades across several countries, and OXA-48-like carbapenemases are one of the main determinants of carbapenem resistance in Enterobacterales. Cefepime\/enmetazobactam is a novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination that demonstrated excellent intrapulmonary penetration, supporting its use in the treatment of pneumonia. This study examined the efficacy of enmetazobactam, in combination with cefepime, compared to carbapenems for OXA-48-producing\n              <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n              in a 24-h murine neutropenic pneumonia model. The combination showed a bacteriostatic effect using the 2-h controls as reference. Compared to 24-h controls, and to cefepime or meropenem monotherapies, the co-administration of enmetazobactam with cefepime demonstrated a pronounced\n              <jats:italic>in vivo<\/jats:italic>\n              bactericidal activity against cefepime-non-susceptible\n              <jats:italic>K. pneumoniae<\/jats:italic>\n              isolates with cefepime\/enmetazobactam MICs up to 8 \u00b5g\/mL in this model.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/spectrum.02345-24","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T13:39:21Z","timestamp":1730381961000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["<i>In vivo<\/i>\n            efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing\n            <i>Klebsiella pneumoniae<\/i>"],"prefix":"10.1128","volume":"12","author":[{"given":"S.","family":"Albac","sequence":"first","affiliation":[{"name":"Vivexia","place":["Dijon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Anzala","sequence":"additional","affiliation":[{"name":"Vivexia","place":["Dijon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chavanet","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Infectiologie, Centre Hospitalier Universitaire","place":["Dijon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dunkel","sequence":"additional","affiliation":[{"name":"Advanz Pharma","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Quevedo","sequence":"additional","affiliation":[{"name":"Advanz Pharma","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Santerre Henriksen","sequence":"additional","affiliation":[{"name":"Maxel Consulting","place":["Jyllinge, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8744-5832","authenticated-orcid":true,"given":"D.","family":"Croisier","sequence":"additional","affiliation":[{"name":"Vivexia","place":["Dijon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05980-0"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2016.014"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04285-6"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003553"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad038"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1222343"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00216-22"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.07.005"},{"key":"e_1_3_4_10_2","unstructured":"World Health Organization. 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed. Available from: https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Retrieved 22 Jan 2024."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12565"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01793-21"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-19"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-19"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-20"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00180-20"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00033-15"},{"key":"e_1_3_4_18_2","volume-title":"In vivo efficacy of enmetazobactam combined with cefepime in a neutropenic murine OXA-48 Klebsiella pneumoniae pneumonia model. Barcelone","author":"Albac S","year":"2024","unstructured":"Albac S. 2024. In vivo efficacy of enmetazobactam combined with cefepime in a neutropenic murine OXA-48 Klebsiella pneumoniae pneumonia model. Barcelone."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01648-19"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.5.679"},{"key":"e_1_3_4_21_2","volume-title":"Exploring in vivo pharmacodynamics (PK\/PD) of Rifampin (RIF) against carbapenem-resistant Acinetobacter baumannii (CRAB) in a pneumonia model to support breakpoints considerations. Poster. Copenhague","author":"Croisier D","year":"2023","unstructured":"Croisier D. 2023. Exploring in vivo pharmacodynamics (PK\/PD) of Rifampin (RIF) against carbapenem-resistant Acinetobacter baumannii (CRAB) in a pneumonia model to support breakpoints considerations. Poster. Copenhague."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01468-20"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.1941-1947.2004"},{"key":"e_1_3_4_25_2","volume-title":"AMR Conference","author":"Croisier D","year":"2023","unstructured":"Croisier D. 2023. Oral session. AMR Conference; Basel."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac425"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01947-13"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06069-11"},{"key":"e_1_3_4_29_2","volume-title":"Pharmacodynamic evaluation of AAI101, a novel extended-spectrum beta-lactamase inhibitor (BLI), with piperacillin against ESBL producers in a hollow fiber infection model","author":"Louie A","year":"2015","unstructured":"Louie A, Kurhanewicz S, Robbins N, Liu W, Fikes S, Brown D, Shapiro S, Pypstra R, Drusano GL. 2015. Pharmacodynamic evaluation of AAI101, a novel extended-spectrum beta-lactamase inhibitor (BLI), with piperacillin against ESBL producers in a hollow fiber infection model."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2210"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06121-11"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01074-18"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01983-20"},{"key":"e_1_3_4_34_2","volume-title":"Development of a new Acinetobacter baumannii pneumonia rabbit model for best-in-class anti-infectives preclinical evaluation. Poster. Coppenhague","author":"Croisier D","year":"2023","unstructured":"Croisier D, Sandrine A, Anzala N, Chavanet P, Bonnot D. 2023. Development of a new Acinetobacter baumannii pneumonia rabbit model for best-in-class anti-infectives preclinical evaluation. Poster. Coppenhague."},{"key":"e_1_3_4_35_2","unstructured":"ISO STANDARD. 2019. ISO 20776-1:2019. ISO. Available from: https:\/\/www.iso.org\/standard\/70464.html. Retrieved 8 Mar 2024."},{"key":"e_1_3_4_36_2","unstructured":"EUCAST. 1997 Available from: https:\/\/www.eucast.org\/"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02345-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02345-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:03:56Z","timestamp":1733407436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.02345-24"}},"subtitle":[],"editor":[{"given":"Aude A.","family":"Ferran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,5]]}},"alternative-id":["10.1128\/spectrum.02345-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.02345-24","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"2024-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02345-24"}}